SCREENING FOR MEDULLARY CARCINOMA IN PEOPLE WITH THYROID NODULES
Abstract
Background/Aim: Medullary thyroid cancer (MTC) is a rare neuroendocrine neoplasm, which arises from parafollicular C cells, which secrete calcitonin. Calcitonin is a sensitive tumor marker of MTC, bearing in mind that the majority of patients have elevated values of it. However, there is no consensus on the use of calcitonin as a screening test for the early detection of MTC in individuals with thyroid nodules. The aim of the research was to analyze the possibility of introducing calcitonin as a screening test for the early detection of MTC through a case report.
Case report: The paper presents a 56-year-old female patient who, during a systematic examination, was found to have nodules with a diameter of 10 x 8 mm and 5 x 4 mm in the right lobe of the thyroid gland. Laboratory analysis revealed slightly elevated calcitonin values (7.8 pg/mL, reference values < 4.8 pg/mL). The calcium stimulation test was within the reference range, and the carcino-embryonic antigen values were normal. Cytological examination of fine-needle aspiration puncture samples corresponded to category T2 according to the Bethesda classification (Chronic lymphocytic thyroiditis of the Hashimoto type). At the control examination, carried out after 6 months, calcitonin values did not differ significantly compared to the original ones.
Conclusion: In the presented patient, the discreetly elevated concentration of calcitonin in the serum did not imply the presence of MTC. Further randomized clinical trials are needed to resolve controversies and establish uniform guidelines for the introduction of calcitonin as a screening test for MTC in individuals with thyroid nodules.
References
Kojić-Katović S. Vasilj A. Preoperacijska dijagnostika medularnog karcinoma štitnjače s osvrtom na citomorfološke značajke i diferencijalnu dijagnozu primarnih i sekundarnih tumora štitnjače. Acta Med Croatica. 2014;68:383. Dostupno na: https://hrcak.srce.hr/file/209793
Master SR, Burns B. Medullary Thyroid Cancer. [Updated 2023 Feb 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Dostupno na: https://www.ncbi.nlm.nih.gov/books/NBK459354/
Bae YJ, Schaab M, Kratzsch J. Calcitonin as Biomarker for the Medullary Thyroid Carcinoma. Recent Results Cancer Res. 2015; 204:117-37. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/26494386/
Cote GJ, Grubbs EG, Hofmann MC. Thyroid C-Cell Biology and Oncogenic Transformation. Recent Results Cancer Res. 2015; 204:1-39. Dostupno na: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640981/
Verbeek HH, de Groot JWB, Sluiter WJ, Muller Kobold AC, van den Heuvel ER, Plukker JT et al. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules. Cochrane Database Syst Rev. 2020; 3(3):CD010159. Dostupno na: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075519/
Faggiano A, Giannetta E, Modica R, Albertelli M, Barba L, Dolce P. Calcium-stimulated calcitonin test for the diagnosis of medullary thyroid cancer: results of a multicenter study and comparison between different assays. Minerva Endocrinology 2023; 48(3):253-60. Dostupno na: https://www.minervamedica.it/en/journals/minervaendocrinology/article.php?cod=R07Y2023N03A0253
Vardarli I, Weber M, Weidemann F, Führer D, Herrmann K, Görges R. Diagnostic accuracy of routine calcitonin measurement for the detection of medullary thyroid carcinoma in the management of patients with nodular thyroid disease: a meta-analysis. Endocr Connect. 2021; 10(3):358-370. Dostupno na: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052568/
Janić T, Stojković M, Klet S, Marković B, Nedeljković BB, Ćirić J, et al. Agresivni klinički tok medularnog mikrokarcinoma štitaste žlezde. Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma 'Zlatibor'. 2022; 27(85):63-81. Dostupno na: https://scindeks-clanci.ceon.rs/data/pdf/1821-1925/2022/1821-19252285063J.pdf
Piticchio T, Frasca F, Trimboli, P. Prevalence and significance of indeterminate calcitonin values in patients with thyroid nodules: A systematic review and meta-analysis. Rev Endocr Metab Disord. 2023; 24:685–694 . Dostupno na: https://doi.org/10.1007/s11154-023-09811-7
Fugazzola L. Stimulated calcitonin cut-offs by different tests. Eur Thyroid J. 2013; 2(1):49-56. Dostupno na: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821495/
Toledo SP, Lourenço DM Jr, Santos MA, Tavares MR, Toledo RA, Correia-Deur JE. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo). 2009; 64(7):699-706. Dostupno na: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710445/
Leboeuf R, Langlois MF, Martin M, Ahnadi CE, Fink GD. Hook Effect” in Calcitonin Immunoradiometric Assay in Patients with Metastatic Medullary Thyroid Carcinoma: Case Report and Review of the Literature, The Journal of Clinical Endocrinology & Metabolism. 2006; 91(2):361–364. Dostupno na: https://doi.org/10.1210/jc.2005-1429
Pieruzzi L, Molinaro E, Agate L, Bottici V, Torregrossa L, Ugolini C et al. Significant difference between the prevalence of C cell hyperplasia (CCH) in benign thyroid nodules without histological thyroiditis (HT) and in papillary/follicular thyroid cancers (PTC/FTC) at histology. Endocrine Abstracts. 2017; 49:EP1414. Dostupno na: https://www.endocrine-abstracts.org/ea/0049/ea0049ep1414
Gambardella C, Offi C, Patrone R, Clarizia G, Mauriello C, Tartaglia E et al. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma? BMC Endocr Disord. 2019;19(Suppl 1):45. Dostupno na: https://doi.org/10.1186/s12902-019-0367-2
Broecker-Preuss M, Simon D, Fries M, Kornely E, Weber M, Vardarli I e al. Update on Calcitonin Screening for Medullary Thyroid Carcinoma and the Results of a Retrospective Analysis of 12,984 Patients with Thyroid Nodules. Cancers. 2023; 15(8):2333. Dostupno na: https://doi.org/10.3390/cancers15082333
Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S et al. Predictive Value of Serum Calcitonin Levels for Preoperative Diagnosis of Medullary Thyroid Carcinoma in a Cohort of 5817 Consecutive Patients with Thyroid Nodules, The Journal of Clinical Endocrinology & Metabolism. 2007; 92(1):450–455. Dostupno na: https://academic.oup.com/jcem/article/92/2/450/2566771?login=false
Kevin Cheung, Sanziana A. Roman, Tracy S. Wang, Hugh D. Walker, Julie Ann Sosa, Calcitonin Measurement in the Evaluation of Thyroid Nodules in the United States: A Cost-Effectiveness and Decision Analysis, The Journal of Clinical Endocrinology & Metabolism.2008; 93(6):2173–2180. Dostupno na: https://academic.oup.com/jcem/article/93/6/2173/2598554
Janić T, Stojković M, Klet S, Marković B, Nedeljković BB, Ćirić J, et al. Agresivni klinički tok medularnog mikrokarcinoma štitaste žlezde. Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma 'Zlatibor'. 2022; 27(85):63-81. Dostupno na: https://scindeks.ceon.rs/article.aspx?artid=1821-19252285063J
Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M. Calcitonin Measurement to Detect Medullary Thyroid Carcinoma in Nodular Goiter: German Evidence-Based Consensus Recommendation. Clin Endocrinol Diabetes. 2004; 112(1): 52-58. Dostupno na https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2004-815727#A367-1